Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
❤️Conditions & CarePhoto: Medical Xpress
Key points
- Cell-free RNA in blood plasma can act as a proxy for the tumor microenvironment.
- Patients with a specific 'lymph node-like' genetic signature showed an 80% lower risk of cancer progression.
- The test offers a non-invasive alternative to bone marrow or tissue biopsies.
A collaborative study between Cornell University and the Dana-Farber Cancer Institute suggests that a simple blood test could identify which patients are most likely to remain in remission following CAR T-cell therapy for large B-cell lymphoma. Published in Cell Reports Medicine, the findings indicate that fragments of cell-free RNA circulating in the blood can reveal the state of a tumor's local environment, providing a non-invasive alternative to traditional tissue biopsies.
The study analyzed plasma samples from 91 patients, revealing that those with a specific genetic signature—resembling the structure of a lymph node—had an 80% lower risk of cancer progression one year after treatment. Unlike previous methods that required invasive tissue sampling, this plasma-based approach reflects the tumor's microenvironment directly. Researchers noted that the signature was not found in circulating immune cells, suggesting it is a unique indicator of tissue-level activity.
While CAR T-cell therapy has significantly improved outcomes for blood cancer patients, nearly half of those treated either do not respond or experience a relapse within a year. This new diagnostic tool aims to address that uncertainty. However, as this research is based on observational analysis of patient cohorts, further clinical validation is required before it can be implemented in standard medical practice. Patients should always consult with their oncology care team regarding individual treatment plans and diagnostic options.
What to know: High levels of a specific RNA signature in blood plasma were linked to better long-term outcomes in lymphoma patients undergoing CAR T-cell therapy, offering a potential non-invasive way to predict treatment success.
Source Medical Xpress — medicalxpress.com/news/2026-11-blood-reveal-lymphoma-patients-immunothe… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…